Business Description
Cellectis SA
ISIN : FR0010425595
Compare
Compare
Traded in other countries / regions
ALCLS.FranceCLLS.USA0WA2.UKZVA.Germany IPO Date
2018-01-08Description
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.85 | |||||
| Equity-to-Asset | 0.33 | |||||
| Debt-to-Equity | 0.71 | |||||
| Debt-to-EBITDA | -1.54 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -1.3 | |||||
| Beneish M-Score | -4.01 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -77 | |||||
| 3-Year EBITDA Growth Rate | -21.1 | |||||
| 3-Year EPS without NRI Growth Rate | -44.9 | |||||
| 3-Year FCF Growth Rate | 44.4 | |||||
| 3-Year Book Growth Rate | -41.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 72.41 | |||||
| Future 3-5Y Total Revenue Growth Rate | 191.68 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 98.74 | |||||
| 9-Day RSI | 91.27 | |||||
| 14-Day RSI | 79.91 | |||||
| 6-1 Month Momentum % | -33.17 | |||||
| 12-1 Month Momentum % | -32.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.78 | |||||
| Quick Ratio | 1.78 | |||||
| Cash Ratio | 1.57 | |||||
| Days Sales Outstanding | 95.73 | |||||
| Days Payable | 40309.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18.8 | |||||
| Shareholder Yield % | -65.61 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 99.42 | |||||
| Operating Margin % | -271.73 | |||||
| Net Margin % | -291.89 | |||||
| FCF Margin % | 211.29 | |||||
| ROE % | -79.45 | |||||
| ROA % | -24.74 | |||||
| ROIC % | -36.61 | |||||
| ROC (Joel Greenblatt) % | -87.47 | |||||
| ROCE % | -37.98 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Price-to-Owner-Earnings | 6.87 | |||||
| PS Ratio | 7.2 | |||||
| PB Ratio | 1.69 | |||||
| Price-to-Tangible-Book | 1.69 | |||||
| Price-to-Free-Cash-Flow | 2.42 | |||||
| Price-to-Operating-Cash-Flow | 2.34 | |||||
| EV-to-EBIT | -0.45 | |||||
| EV-to-EBITDA | -0.59 | |||||
| EV-to-Revenue | 1.2 | |||||
| EV-to-Forward-Revenue | 12.18 | |||||
| EV-to-FCF | 0.52 | |||||
| Price-to-Net-Current-Asset-Value | 7.78 | |||||
| Earnings Yield (Greenblatt) % | -221.56 | |||||
| FCF Yield % | 28.97 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cellectis SA Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 26.511 | ||
| EPS (TTM) (€) | -1.229 | ||
| Beta | 3.18 | ||
| Volatility % | 211.84 | ||
| 14-Day RSI | 79.91 | ||
| 14-Day ATR (€) | 0.027364 | ||
| 20-Day SMA (€) | 1.7721 | ||
| 12-1 Month Momentum % | -32.89 | ||
| 52-Week Range (€) | 1.638 - 3.426 | ||
| Shares Outstanding (Mil) | 100.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cellectis SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cellectis SA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cellectis SA Frequently Asked Questions
What is Cellectis SA(LTS:0WA2)'s stock price today?
The current price of LTS:0WA2 is €1.94. The 52 week high of LTS:0WA2 is €3.43 and 52 week low is €1.64.
When is next earnings date of Cellectis SA(LTS:0WA2)?
The next earnings date of Cellectis SA(LTS:0WA2) is 2025-02-04 Est..
Does Cellectis SA(LTS:0WA2) pay dividends? If so, how much?
Cellectis SA(LTS:0WA2) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers